Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-07T23:57:54.413Z Has data issue: false hasContentIssue false
  • English
  • Français

Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides

Published online by Cambridge University Press:  23 March 2009

Paul J. White ,
Frank Anastasopoulos ,
Colin W. Pouton  and
Ben J. Boyd
Paul J. White*
Affiliation:
Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
Frank Anastasopoulos
Affiliation:
Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia. Clinical Vision Research Australia, Victorian College of Optometry, Carlton, Victoria 3053, Australia.
Colin W. Pouton
Affiliation:
Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
Ben J. Boyd
Affiliation:
Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
*
*Corresponding author: Paul J. White, Medicinal Chemistry and Drug Action, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia. Tel: +613 99039074; Fax: +613 99039638; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Antisense oligonucleotides as a therapeutic platform have been slow to progress since the approval of the first antisense drug in 1998. Recently, there have been several examples of convincing antisense interventions in animal models and promising clinical trial data. This review considers the factors determining the success of antisense oligonucleotides as therapeutic agents. In order to produce target knockdown after systemic delivery, antisense oligonucleotides must avoid nuclease degradation, reticuloendothelial-system uptake and rapid renal excretion, and extravasate to the target cell type outside the vasculature. They then must enter the target cell, and escape the endosome–lysosome pathway so as to be free to interact with the target mRNA. We consider the significance of these limiting factors based on the literature and our own experience using systemic administration of antisense oligonucleotides.

Type
Review Article
Information
Expert Reviews in Molecular Medicine , Volume 11 , July 2009 , e10
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

1Kastelein, J.J.P. et al. (2006) Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114, 1729-1735Google Scholar
2Lemonidis, K.M. et al. (2006) Pharmacological profiling of apolipoprotein B-100 and microsomal triglyceride transfer protein antisense inhibitors in hyperlipidemic mice. Arteriosclerosis, Thrombosis, and Vascular Biology 26, E60-E61Google Scholar
3Wang, Y. (2007) Isis-301012 - Antisense inhibitor of apolipoprotein B treatment of lipoprotein disorders. Drugs of the Future 32, 699-702Google Scholar
4Aartsma-Rus, A. et al. (2004) Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. Gene Therapy 11, 1391-1398Google Scholar
5Alter, J. et al. (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nature Medicine 12, 175-177Google Scholar
6Arechavala, V. et al. (2006) A phase I/II clinical trial in Duchenne muscular dystrophy using IM and IV delivered antisense oligonucleotides: The MDEX consortium. Neuromuscular Disorders 16, 685Google Scholar
7McHutchison, J.G. et al. (2006) A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. Journal of Hepatology 44, 88-96Google Scholar
8Devi, G.R. et al. (2005) In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clinical Cancer Research 11, 3930-3938CrossRefGoogle ScholarPubMed
9Iversen, P.L. et al. (2003) Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a phase I safety study in humans. Clinical Cancer Research 9, 2510-2519Google Scholar
10Leonetti, C. et al. (1996) Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice. Journal of the National Cancer Institute 88, 419-429CrossRefGoogle ScholarPubMed
11Crooke, S.T. (2004) Progress in antisense technology. Annual Review of Medicine 55, 61-95Google Scholar
12Galderisi, U., Cascino, A. and Giordano, A. (1999) Antisense oligonucleotides as therapeutic agents. Journal of Cellular Physiology 181, 251-257Google Scholar
13Kastelein, J.P. et al. (2007) ISIS 301012, an antisense inhibitor of APOB, produces significant additional reduction of LDL-C & APOB in hypercholesterolemic subjects on statins not meeting target. Atherosclerosis Supplements 8, 198-199CrossRefGoogle Scholar
14Yin, H., Lu, Q. and Wood, M. (2008) Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Molecular Therapy 16, 38-45CrossRefGoogle ScholarPubMed
15Madsen, E.C. et al. (2008) In vivo correction of a Menkes disease model using antisense oligonucleotides. Proceedings of the National Academy of Sciences of the United States of America 105, 3909-3914CrossRefGoogle Scholar
16Henke, E. et al. (2008) Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nature Biotechnology 26, 91-100Google Scholar
17Urban, E. and Noe, C.R. (2003) Structural modifications of antisense oligonucleotides. Farmaco 58, 243-258CrossRefGoogle ScholarPubMed
18Kaur, H., Babu, B.R. and Maiti, S. (2007) Perspectives on chemistry and therapeutic applications of Locked Nucleic Acid (LNA). Chemical Reviews 107, 4672-4697Google Scholar
19Faria, M. and Ulrich, H. (2008) Sugar boost: when ribose modifications improve oligonucleotide performance. Current Opinion in Molecular Therapeutics 10, 168-175Google ScholarPubMed
20Prakash, T.P. and Bhat, B. (2007) 2'-Modified oligonucleotides for antisense therapeutics. Current Topics in Medicinal Chemistry 7, 641-649Google Scholar
21Crooke, S., ed. (2008) Antisense Drug Technology; Principles, Strategies and Applications, CRC Press, Boca Raton, FL, USAGoogle Scholar
22Iversen, P.L. (2001) Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation. Current Opinion in Molecular Therapeutics 3, 235-238Google Scholar
23Nielsen, E. (2006) RNA targeting using peptide nucleic acid. Handbook of Experimental Pharmacology 395-403Google Scholar
24Jepsen, J.S., Sorensen, M.D. and Wengel, J. (2004) Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology. Oligonucleotides 14, 130-146CrossRefGoogle ScholarPubMed
25Monia, B.P. et al. (1993) Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. Journal of Biological Chemistry 268, 14514-14522CrossRefGoogle Scholar
26Fluiter, K. et al. (2005) On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. Chembiochem 6, 1104-1109Google Scholar
27Grunweller, A. et al. (2003) Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Research 31, 3185-3193Google Scholar
28Monia, B.P. et al. (1993) Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. Journal of Biological Chemistry 268, 14514-14522Google Scholar
29Yu, R.Z. et al. (2007) Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metabolism and Disposition 35, 460-468Google Scholar
30McMahon, B.M. et al. (2002) Pharmacokinetics and tissue distribution of a peptide nucleic acid after intravenous administration. Antisense and Nucleic Acid Drug Development 12, 65-70Google Scholar
31Yu, R.Z. et al. (2004) Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. Journal of Pharmaceutical Sciences 93, 48-59Google Scholar
32Raoof, A.A. et al. (2004) Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate. Journal of Pharmaceutical Sciences 93, 1431-1439Google Scholar
33Zhang, R. et al. (1995) Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochemical Pharmacology 49, 929-939Google Scholar
34Sewell, K.L. et al. (2002) Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. Journal of Pharmacology and Experimental Therapeutics 303, 1334-1343Google Scholar
35Marcucci, G. et al. (2003) Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 101, 425-432Google Scholar
36Cossum, P.A. et al. (1994) Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. Journal of Pharmacology and Experimental Therapeutics 269, 89-94Google Scholar
37Barbee, R.W. et al. (1992) Microsphere and dilution techniques for the determination of blood flows and volumes in conscious mice. American Journal of Physiology 263, R728-733Google ScholarPubMed
38Delp, M.D. et al. (1991) Distribution of cardiac output during diurnal changes of activity in rats. American Journal of Physiology 261, H1487-1493Google ScholarPubMed
39Geary, R.S. et al. (1997) Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metabolism and Disposition 25, 1272-1281Google Scholar
40Geary, R.S. et al. (2003) Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: Comparison across species. Drug Metabolism and Disposition 31, 1419-1428CrossRefGoogle ScholarPubMed
41Rayburn, E.R. and Zhang, R. (2008) Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discovery Today 13, 513-521CrossRefGoogle ScholarPubMed
42AEGIS (1997) Hybridon stops development of Gem(R)91 for AIDS; resources to be focused on four 2nd generation compounds, http://www.aegis.com/news/pr/1997/PR970720.htmlGoogle Scholar
43Roivainen, A. et al. (2004) 68 Ga-labeled oligonucleotides for in vivo imaging with PET. Journal of Nuclear Medicine 45, 347-355Google Scholar
44Lendvai, G. et al. (2005) Biodistribution of 68 Ga-labelled phosphodiester, phosphorothioate, and 2’-O-methyl phosphodiester oligonucleotides in normal rats. European Journal of Pharmaceutical Sciences 26, 26-38Google Scholar
45Kuhnast, B. et al. (2000) General method to label antisense oligonucleotides with radioactive halogens for pharmacological and imaging studies. Bioconjugate Chemistry 11, 627-636Google Scholar
46Fluiter, K. et al. (2003) In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides. Nucleic Acids Research 31, 953-962Google Scholar
47Agrawal, S. et al. (1997) Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proceedings of the National Academy of Sciences of the United States of America 94, 2620-2625Google Scholar
48Amantana, A. et al. (2007) Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjugate Chemistry 18, 1325-1331Google Scholar
49Sawai, K. et al. (1996) Disposition of oligonucleotides in isolated perfused rat kidney: involvement of scavenger receptors in their renal uptake. Journal of Pharmacology and Experimental Therapeutics 279, 284-290Google Scholar
50Geary, R.S. et al. (2001) Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. Journal of Pharmacology and Experimental Therapeutics 296, 890-897Google Scholar
51Sazani, P. et al. (2002) Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nature Biotechnology 20, 1228-1233CrossRefGoogle ScholarPubMed
52Rappaport, J. et al. (1995) Transport of phosphorothioate oligonucleotides in kidney: implications for molecular therapy. Kidney International 47, 1462-1469Google Scholar
53Oberbauer, R., Schreiner, G.F. and Meyer, T.W. (1995) Renal uptake of an 18-mer phosphorothioate oligonucleotide. Kidney International 48, 1226-1232Google Scholar
54Masarjian, L. et al. (2004) Distribution and excretion of a phosphorothioate oligonucleotide in rats with experimentally induced renal injury. Oligonucleotides 14, 299-310Google Scholar
55Monteith, D.K. et al. (1999) Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys. Toxicologic Pathology 27, 307-317Google Scholar
56Sawai, K. et al. (1995) Renal disposition characteristics of oligonucleotides modified at terminal linkages in the perfused rat kidney. Antisense Research and Development 5, 279-287Google Scholar
57Steward, A. et al. (1998) Co-administration of polyanions with a phosphorothioate oligodeoxynucleotide (CGP 69846A): a role for the scavenger receptor in its in vivo disposition. Biochemical Pharmacology 56, 509-516Google Scholar
58Lendvai, G. et al. (2008) Biodistribution of 68 Ga-labeled LNA-DNA mixmer antisense oligonucleotides for rat chromogranin-A. Oligonucleotides 18, 33-49CrossRefGoogle Scholar
59Wallace, T.L. et al. (1997) Pharmacokinetics and distribution of a 33P-labeled anti-human immunodeficiency virus oligonucleotide (AR177) after single- and multiple-dose intravenous administration to rats. Journal of Pharmacology and Experimental Therapeutics 280, 1480-1488Google Scholar
60Butler, M., Stecker, K. and Bennett, C.F. (1997) Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Laboratory Investigation 77, 379-388Google Scholar
61Graham, M.J. et al. (1998) In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. Journal of Pharmacology and Experimental Therapeutics 286, 447-458Google Scholar
62Butler, M. et al. (2000) Phosphorothioate oligodeoxynucleotides distribute similarly in class A scavenger receptor knockout and wild-type mice. Journal of Pharmacology and Experimental Therapeutics 292, 489-496Google Scholar
63Bijsterbosch, M.K. et al. (2002) bis-Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides are highly selectively taken up by the liver. Journal of Pharmacology and Experimental Therapeutics 302, 619-626Google Scholar
64Yu, R.Z. et al. (1999) Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-ras encapsulated in stealth liposomes. Pharmaceutical Research 16, 1309-1315Google Scholar
65Ponnappa, B.C. et al. (2005) Inhibition of tumor necrosis factor alpha secretion and prevention of liver injury in ethanol-fed rats by antisense oligonucleotides. Biochemical Pharmacology 69, 569-577CrossRefGoogle ScholarPubMed
66Tyler, B.M. et al. (1999) Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression. Proceedings of the National Academy of Sciences of the United States of America 96, 7053-7058Google Scholar
67Greish, K. et al. (2003) Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clinical Pharmacokinetics 42, 1089-1105CrossRefGoogle ScholarPubMed
68White, P.J. et al. (1999) Live confocal microscopy of oligonucleotide uptake by keratinocytes in human skin grafts on nude mice. Journal of Investigative Dermatology 112, 887-892Google Scholar
69White, P.J. et al. (1999) Oligonucleotide uptake in cultured keratinocytes: influence of confluence, cationic liposomes, and keratinocyte cell type. Journal of Investigative Dermatology 112, 699-705CrossRefGoogle ScholarPubMed
70Dick, J.M. et al. (2001) Antisense knockdown of inducible nitric oxide synthase inhibits the relaxant effect of VIP in isolated smooth muscle cells of the mouse gastric fundus. British Journal of Pharmacology 134, 425-433Google Scholar
71Roth, C.M. (2005) Molecular and cellular barriers limiting the effectiveness of antisense oligonucleotides. Biophysical Journal 89, 2286-2295CrossRefGoogle ScholarPubMed
72Roberts, J. et al. (2006) Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. Molecular Therapy 14, 471-475Google Scholar
73Astriab-Fisher, A. et al. (2002) Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions. Pharmaceutical Research 19, 744-754Google Scholar
74Astriab-Fisher, A. et al. (2000) Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates. Biochemical Pharmacology 60, 83-90Google Scholar
75Juliano, R. et al. (2008) Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Research 36, 4158-4171Google Scholar
76Seong, J.H. et al. (2006) Polyethylenimine-based antisense oligodeoxynucleotides of IL-4 suppress the production of IL-4 in a murine model of airway inflammation. Journal of Gene Medicine 8, 314-323Google Scholar
77Fischer, D. et al. (2004) Effect of poly(ethylene imine) molecular weight and pegylation on organ distribution and pharmacokinetics of polyplexes with oligodeoxynucleotides in mice. Drug Metabolism and Disposition 32, 983-992Google Scholar
78Kilic, A.C. et al. (2005) Preparation and characterization of PLGA nanospheres for the targeted delivery of NR2B-specific antisense oligonucleotides to the NMDA receptors in the brain. Journal of Microencapsulation 22, 633-641Google Scholar
79Springate, C.M. et al. (2008) Clusterin antisense complexed with chitosan for controlled intratumoral delivery. International Journal of Pharmaceutics 350, 53-64Google Scholar
80Boyd, B.J. et al. (2006) Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats. Molecular Pharmaceutics 3, 614-627Google Scholar
81Yoo, H., Sazani, P. and Juliano, R.L. (1999) PAMAM dendrimers as delivery agents for antisense oligonucleotides. Pharmaceutical Research 16, 1799-1804Google Scholar
82Kaminskas, L.M. et al. (2008) The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers. Molecular Pharmaceutics 5, 449-463Google Scholar
83Dash, P.R. et al. (1999) Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery. Gene Therapy 6, 643-650Google Scholar
84Merdan, T. et al. (2005) PEGylation of poly(ethylene imine) affects stability of complexes with plasmid DNA under in vivo conditions in a dose-dependent manner after intravenous injection into mice. Bioconjugate Chemistry 16, 785-792Google Scholar
85Ward, C.M., Read, M.L. and Seymour, L.W. (2001) Systemic circulation of poly(L-lysine)/DNA vectors is influenced by polycation molecular weight and type of DNA: differential circulation in mice and rats and the implications for human gene therapy. Blood 97, 2221-2229Google Scholar
86Anwer, K. et al. (2000) Cationic lipid-based delivery system for systemic cancer gene therapy. Cancer Gene Therapy 7, 1156-1164Google Scholar
87Hofland, H.E. et al. (1997) In vivo gene transfer by intravenous administration of stable cationic lipid/DNA complex. Pharmaceutical Research 14, 742-749Google Scholar
88Liu, F. et al. (1997) Factors controlling the efficiency of cationic lipid-mediated transfection in vivo via intravenous administration. Gene Therapy 4, 517-523Google Scholar
89Mahato, R.I. et al. (1998) Biodistribution and gene expression of lipid/plasmid complexes after systemic administration. Human Gene Therapy 9, 2083-2099Google Scholar
90Szoka, F. (2008) Molecular biology. The art of assembly. Science 319, 578-579Google Scholar
91Li, W. and Szoka, F.C. Jr. (2007) Lipid-based nanoparticles for nucleic acid delivery. Pharmaceutical Research 24, 438-449Google Scholar
92Peer, D. et al. (2008) Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 319, 627-630CrossRefGoogle ScholarPubMed
93Rozema, D.B. et al. (2007) Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proceedings of the National Academy of Sciences of the United States of America 104, 12982-12987Google Scholar
94Wolff, J.A. and Rozema, D.B. (2008) Breaking the bonds: non-viral vectors become chemically dynamic. Molecular Therapy 16, 8-15Google Scholar
95Stein, C.A. and Krieg, A.M. (1994) Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Research and Development 4, 67-69Google Scholar
96Nguyen, T.T. et al. (2006) Intravenous insulin-like growth factor-I receptor antisense treatment reduces angiotensin receptor expression and function in spontaneously hypertensive rats. Journal of Pharmacology and Experimental Therapeutics 318, 1171-1177Google Scholar
97Nguyen, T.T. and White, P.J. (2005) Intravenous IGF-I receptor antisense reduces IGF-IR expression and diminishes pressor responses to angiotensin II in conscious normotensive rats. British Journal of Pharmacology 146, 935-941Google Scholar
98Kagiyama, S. et al. (2003) Antisense to epidermal growth factor receptor prevents the development of left ventricular hypertrophy. Hypertension 41, 824-829Google Scholar
99Zhang, Y.C. et al. (2000) Antisense inhibition of beta(1)-adrenergic receptor mRNA in a single dose produces a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats. Circulation 101, 682-688Google Scholar
100Lu, Q.L. et al. (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proceedings of the National Academy of Sciences of the United States of America 102, 198-203CrossRefGoogle Scholar
101Crooke, R.M. et al. (2005) An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. Journal of Lipid Research 46, 872-884Google Scholar
102Guha, M. et al. (2007) Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. The FASEB Journal 21, 3355-3368Google Scholar
103Tyler, B.M. et al. (1999) Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression. Proceedings of the National Academy of Sciences of the United States of America 96, 7053-7058CrossRefGoogle Scholar
104Lu, Q.L. et al. (2003) Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nature Medicine 9, 1009-1014CrossRefGoogle ScholarPubMed
105Alter, J. et al. (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nature Medicine 12, 175-177Google Scholar
106Yin, H.F., Lu, Q.L. and Wood, M. (2008) Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Molecular Therapy 16, 38-45Google Scholar
107Reich, S.J. et al. (2003) Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Molecular Vision 9, 210-216Google Scholar
108Xing, H.R. et al. (2003) Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer. Nature Medicine 9, 1266-1268CrossRefGoogle ScholarPubMed
109Sazani, P. et al. (2001) Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Research 29, 3965-3974CrossRefGoogle ScholarPubMed
110Cao, N. et al. (2006) Characterization of the acute cardiovascular effects of intravenously administered insulin-like growth factor-I in conscious Sprague-Dawley rats. Clinical and Experimental Pharmacology and Physiology 33, 1190-1195CrossRefGoogle ScholarPubMed
111Myers, K.J. et al. (2005) Antisense oligonucleotide blockade of alpha 4 integrin prevents and reverses clinical symptoms in murine experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 160, 12-24Google Scholar
112Lau, Q.C. et al. (2002) In vivo pro-apoptotic and antitumor efficacy of a c-Raf antisense phosphorothioate oligonucleotide: relationship to tumor size. Antisense and Nucleic Acid Drug Development 12, 11-20Google Scholar
113Xing, H.R. et al. (2003) Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer. Nature Medicine 9, 1266-1268Google Scholar
114Kastelein, J.J. et al. (2006) Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114, 1729-1735Google Scholar
115van Deventer, S.J., Tami, J.A. and Wedel, M.K. (2004) A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 53, 1646-1651Google Scholar
116Group, V.S. (2002) A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. American Journal of Ophthalmology 133, 467-474Google Scholar
117Cunningham, C.C. et al. (2001) A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer 92, 1265-1271Google Scholar
118Cunningham, C.C. et al. (2000) A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clinical Cancer Research 6, 1626-1631Google Scholar
119Marshall, J. et al. (2004) A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Annals of Oncology 15, 1274-1283Google Scholar
120Adjei, A.A. et al. (2003) A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clinical Cancer Research 9, 115-123Google ScholarPubMed
121Mani, S. et al. (2002) Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clinical Cancer Research 8, 1042-1048Google Scholar
122Stevenson, J.P. et al. (1999) Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). Journal of Clinical Oncology 17, 2227-2236Google Scholar
123Bishop, M.R. et al. (1996) Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. Journal of Clinical Oncology 14, 1320-1326Google Scholar
124Bedikian, A.Y. et al. (2006) Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. Journal of Clinical Oncology 24, 4738-4745Google Scholar
125O'Brien, S. et al. (2007) Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. Journal of Clinical Oncology 25, 1114-1120Google Scholar
126Bijsterbosch, M.K. et al. (2002) bis-Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides are highly selectively taken up by the liver. Journal of Pharmacology and Experimental Therapeutics 302, 619-626Google Scholar
127Sun, Y. et al. (2006) Suppression of tumor growth using antisense oligonucleotide against survivin in an orthotopic transplant model of human hepatocellular carcinoma in nude mice. Oligonucleotides 16, 365-374Google Scholar

Further reading, resources and contacts

The RNAi.net website contains breaking news stories, job vacancies, product information and conference information in the field of RNAi: http://www.rnai.net/

Crooke, S., ed. (2008) Antisense Drug Technology; Principles, Strategies and Applications, CRC Press, Boca Raton, FL, USAGoogle Scholar
Rayburn, E.R. and Zhang, R. (2008) Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discovery Today 13, 513-521Google Scholar
Juliano, R. et al. (2008) Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Research 36, 4158-4171Google Scholar
Crooke, S., ed. (2008) Antisense Drug Technology; Principles, Strategies and Applications, CRC Press, Boca Raton, FL, USAGoogle Scholar
Rayburn, E.R. and Zhang, R. (2008) Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discovery Today 13, 513-521Google Scholar
Juliano, R. et al. (2008) Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Research 36, 4158-4171Google Scholar